Uwell Biopharma, Inc. (TPEX:7902)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
46.00
-3.95 (-7.91%)
At close: Feb 26, 2026
489.74%
Market Cap 9.20B
Revenue (ttm) 450.00K
Net Income (ttm) -54.86M
Shares Out 200.00M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,843,206
Average Volume 1,406,019
Open 49.95
Previous Close 49.95
Day's Range 44.90 - 49.95
52-Week Range 7.80 - 51.50
Beta n/a
RSI 70.50
Earnings Date n/a

About Uwell Biopharma

Uwell Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel cancer immunotherapeutic in Taiwan. The company provides chimeric antigen receptor T-cell (CAR-T) therapy platforms, lentiviral vector production, and related services. The company was founded in 2020 and is based in New Taipei City, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2020
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7902
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.